tefibazumab

Tefibazumab is a humanized immunoglobulin G1 kappa (IgG1κ) monoclonal antibody developed for the prevention and treatment of severe infections caused by *Staphylococcus aureus*, including methicillin-resistant *S. aureus* (MRSA). It specifically targets clumping factor A (ClfA), a surface adhesin protein found on virtually all strains of *S. aureus*, which mediates bacterial adhesion to fibrinogen and is classified as an MSCRAMM (microbial surface components recognizing adhesive matrix molecules) protein. By binding ClfA, tefibazumab inhibits the early steps of bacterial colonization and infection, potentially improving clinical outcomes in serious staphylococcal infections. Preclinical studies demonstrated protective effects against sepsis-induced mortality in animal models and enhanced efficacy when combined with vancomycin in infective endocarditis models. Tefibazumab was evaluated as adjunctive therapy in phase 2 trials for indications such as *S. aureus* bacteremia and cystic fibrosis patients with staphylococcal infection but development was suspended before approval[1][3][5][6].

Brand names

Aurexis

Other names

S. aureus monoclonal antibody - InhibitexStaphylococcus aureus monoclonal antibody - Inhibitex